Human blood platelets and viruses: defense mechanism and role in the removal of viral pathogens by Masresha Seyoum , Bamlaku Enawgaw , Mulugeta Melku
REVIEW Open Access
Human blood platelets and viruses: defense
mechanism and role in the removal of viral
pathogens
Masresha Seyoum1,2, Bamlaku Enawgaw2* and Mulugeta Melku2
Abstract
Platelets are small non-nucleated cell fragments and the second most abundant cell that play crucial role in managing
vascular integrity and regulating hemostasis. Recent finding shows, beyond its hemostatic function platelets also play a
main role in fighting against pathogen including viruses. With their receptors, platelet interacts with viral pathogen and
this interaction between platelets and viral pathogens result in activation of platelets. Activated platelet releases
different molecules that have antiviral activity including kinocidins and other platelet microbicidal peptides. In
addition, activated platelet has antiviral role by different mechanism including; phagocytosis of viral pathogen,
produce reactive oxygen species and interact with and activate other immune cells. In other side, antiplatelet
treatments are one of defending mechanism of viral pathogen. This narrative review summarizes what is known
regarding the role of human platelets in fighting viral pathogen.
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Background
Platelets are small discoid shaped non-nucleated cells
with 1-3 μm size in diameter. They originated from bone
marrow megakaryocytes (MKs) cytoplasm and circulate
in the vascular system to play a main role in haemostasis
and thrombosis. In normal healthy individual, platelets
are the second most abundant cells next to red blood
cells (RBCs) with 150,000 – 450,000 cells/μL [1–3].
These number account about 70% of the platelets in the
peripheral blood. The remaining 30% body platelets are
stored in the spleen [3].
Platelets have a main function in hemostasis and blood
coagulation. They involve in the prevention of bleeding
disorders, mainly in the primary hemostasis. Following
vascular injury, sub endothelial collagen is exposed.
Then plasma von Willebrand factor (vWF), which is se-
creted by platelets and endothelial cells, anchor onto the
collagen. Platelet vWF receptor (glycoprotein Ibα) inter-
acts with vWF and initiates platelets to the injured site
[4]. Then they became activated and release different
molecules such as von Willebrand factor (vWF),
thromboxane A2, phospholipids, ADP and others [5].
ADP involved in attraction of more platelets to the in-
jured area and thromboxane A2 promotes platelet aggre-
gation to form platelet plug. This platelet plug
minimizes bleeding and promote blood coagulation
process [4].
Now a day, different evidence showed that platelets
have an ability to interact with and internalize pathogens
including viruses [6–9], beyond their main function in
hemostasis and blood coagulation [4, 5]. These functions
are achieved through direct interaction with leukocytes,
endothelial cells and via release of soluble inflammatory
mediators that enhance recruitment and activation of
leukocytes [6, 10–14].
In addition to binding function, platelets also involve
in phagocytosis by enhancing antigen presentation by
antigen presenting cells [15–18]. But their role in viral
infection response is not fully understood. Their inter-
action to viruses may have benefit or risk for the host.
Therefore, this narrative review aimed to summarize the
current knowledge on the role of blood platelets in fight-
ing viral pathogens. This review focused on new and
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emerging concepts related to defending role and mech-
anism of platelets against viral infections.
Mechanism of human platelets in defending viral
pathogen
On their surface platelets have receptors for viral patho-
gens that facilitate the direct interaction of platelets with
viral pathogens. This interaction between platelets and
viral pathogens through different receptors cause quanti-
tative (thrombocytopenia) and qualitative platelets dys-
function associated with viral pathogen [6, 19–23].
Beside this, the recent findings indicate that platelets
play a main role in defending viral pathogen and has ad-
verse effect against viral infection. It shows that binding
of viral pathogen with platelets not only result in clear-
ance of platelets but also clearance of viral pathogens
caused by platelets [6, 7].
Platelet receptors to recognize viral pathogens
Different receptors that found on the surface of platelets
enable platelets to sense the presence of viral pathogens
[24]. Platelets and megakaryocytes express messenger
ribonucleic acid (mRNA) and/or protein for the toll like
receptors (TLR 1, TLR 2, TLR3, TLR 4, TLR 6, TLR 7,
TLR 8 and TLR 9) that detect and bind viral compo-
nents at the cell surface and viral nucleic acids [9,
25–32]. These TLRs are important for binding of plate-
lets to pathogens such as bacteria, parasites and proto-
zoa and important for their clearance [8, 9, 13, 30, 33].
Also, platelets express several complement receptors,
including CR2, CR3, CR4, C3aR, C5aR, gC1qR and
cC1qR [34]. These complements act as receptor for
pathogens and implements multiple functions in direct
and indirect antimicrobial host defense, including, cell
lysis, opsonization and chemotaxis [35]. Megakaryocytes
express CD4 [36] while both MKs and platelets express
CXCR1, 2, 4 and CCR3 co receptors used for interaction
with HIV-1 [17, 37].
Additionally, platelet granules express Dendritic Cell-
Specific ICAM3-Grabbing Non-integrin (DC-SIGN) [18,
38] and C-type lectin receptor 2 (CLEC-2) ([18, 39])
which are used for the interaction with HIV-1 [18, 38]
Platelet surface receptors such as DC-SIGN or enhance-
ment of the receptor FcγII play important role in bind-
ing of platelets with Dengue virus (DENV). DC-SIGN
and heparin sulphate proteoglycan are receptors for
DENV and the combination of anti–DC-SIGN and low-
molecular-wType equation here.eight heparin prevent
binding of platelets with DENV [19, 22]. DENV infection
leads to thrombocytopenia by increasing phagocytosis of
DV-induced apoptosis platelets by macrophages via a
Phosphatidylserine-recognizing pathway [23, 40].
Among the receptors, alpha v beta 3 (αvβ3) or alpha v
beta 5 (αvβ5) interact with adenoviruses [41] and platelet
glycol proteins GPIa/IIa (α2 β1 integrin) and GPVI (a
member of the Ig super family and primary signalling re-
ceptor for platelet activation by collagen) bind viruses
[42]. Platelets also express Coxsackie-Adeno receptor
(CAR). This receptor is important for the interaction of
Coxsackieviruses B (CVB) with platelets. Although CVB
virus does not replicate in platelets, it triggers P-selectin
and Phosphatidylserine (PS) membrane expression.
Expression of P-selectin and PS as the main mediators
of platelet with leukocyte interactions and promoting
their phagocytosis by macrophages [43].
Although, platelets do not express HCV receptors such
as CD81 [44]; they express glycoprotein VI (GPVI) which
is a receptor used to form interaction between HCV and
platelets [45]. Studies demonstrated that individuals with
HPA-1a/1b, HPA-2b and HPA-5b alleles had a higher risk
for HCV than those individuals with HPA-2a and HPA
-5b alleles [46–48]. Table 1 summarizes different viruses
and their receptors on the platelets.
Pro-inflammatory activity of platelets
After platelets bind and phagocytes infectious micro-
organism, they become activated and undergo degranu-
lation and release a variety of inflammatory mediators,
chemokines and cytokines from their granules. Adeno-
sine diphosphate (ADP), thromboxane A2 (TXA2),
Table 1 Platelet receptors for viruses
Receptor Viruses Reference
αvβ3 Hantaviruses [6, 73, 74]
Coxsackievirus A9, A16,
Human adenovirus type 2
Echovirus 9
Human parechovirus
αIIbβ3 Hantaviruses [6, 73, 74]
α 2β1 Echovirus 1 [75, 76]
Rotavirus
DC-SIGN Lentiviruse, HIV [9, 38]
DC-SIGN Ebola virus [77, 78]
Axl Lassa fever virus (LASV)
Tyro3
CCR-3 & 4, CXCR-1, 2 & 4,
CLEC-2, DC-SIGN
HIV [7, 18]
GP-VI HCV [7, 9]
CR2 EBV [6, 7, 79]
α2β1 Rotavirus [7, 9]
α2bβ3 (GPIIbIIIa) Adenovirus [6, 7]
N.B: CLEC-2: C-type lectin-like type II transmembrane receptor; CR-2: Complement
Receptor type 2; CCR-1, CCR-3, CCR-4: C-C Chemokine Receptor type 1, 3 and 4;
CXCR-1, CXCR-2, CXCR-4: C-X-C chemokine receptor type 1, 2 and 4. DC-SIGN:
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin;
GP-VI: Glycoprotein VI; PAR-1/PAR-4: Platelet Activating Receptor ¼
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serotonin, cytokines (IL-1β, TNFα, TGF- β, CD40L) and
chemokines (CXCL1 (GROa), CXCL4/PF4, CXCL5,
CXCL7, CXCL12, CXCL14, CCL5 (RANTES), CCL3
(MIP1a), MCP-3 (CCL7)) are released. These platelet-
derived chemokines and cytokines stimulate migration
of monocytes and enhances phagocytosis [13, 14, 49–51].
Platelet dense (δ) granules contain nucleotides
(ADP and GTP); bioactive amines (histamine and
serotonin); and bioactive ions (Ca2+ and PO3−) while
alpha (α) granules contain adhesion molecules; plate-
let microbicidal proteins (PMPs) and kinocidins. The
releasing of α - granules provide platelet-mediated
host defense mechanisms, as they contain kinocidins
and microbicidal proteins which is important for anti-
viral host defense [50].
Also, when there was infection, platelets play a main
role in defending pathogens by activating immune cells.
They send signals to immune cells by releasing chemo-
kines that attract and recruit immune cells to the site
of infection [52, 53]. For this function, kinocidins, in
addition to its antimicrobial activity, play the main role
in attraction and activation of phagocytes and lympho-
cytes [54].
The cleaving of kinocidins and antimicrobial peptides
by thrombin and pathogens; give broad and strong anti-
microbial property for platelets. For example, the com-
mon kinocidins, platelet factor 4 (PF-4) which is a
small cytokine belonging to the CXC family, CXCL4,
are inhibitor of HIV-1 and suppresses HIV-1 infection
of T-lymphocytes. [55–57]. Similar to granulocytes,
platelet have direct antimicrobial functions that are me-
diated by secretion of antimicrobial molecules such as
platelet microbicidal peptides (PMPs). PMPs are stored
in platelet granules and can kill microorganisms includ-
ing viruses, when they released during platelet activa-
tion and degranulation [58]. Forexample, platelets show
a direct interaction with HIV-1 through different mech-
anisms such as binding, engulfment, and internaliza-
tion, all of which play a role in host defense during
HIV-1 infection, by limiting viral spread and probably
by inactivating viral particles [59].
Different observation gives evidence for antiviral ac-
tivity of antimicrobial peptides. Nine synthetic anti-
microbial peptides, four originating from thrombin-
induced human platelet-derived antimicrobial proteins
named PD1-PD4 and five synthetic repeats of
arginine-tryptophan repeats (RW1-5) demonstrate for
their antiviral activity for vaccinia virus (VV) [60].
Up on activation platelets also release defensin (α and
β) which have anti-viral role. For example, human alpha-
defensins 1-3 and human alpha-defensin 5 are potent
antagonists of papilloma virus types and human beta-
defensins 1 and 2 displayed little anti- human papilloma
virus activity [61].
Platelet ROS production
Reactive Oxygen Species (ROS) are diffusible and short-
lived molecules that have a major role in platelet activa-
tion regulation. In turn, different observations clearly
indicate that, activated platelets have the capability to
synthesize ROS such as H2O2,
_OH and peroxynitrite
(NO− 3), which are able to modify platelet function [62,
63]. The released ROS from platelets has antimicrobial
role and contribute in defending role of platelets by
killing of pathogens [64]. It is widely accepted that the
ROS produced by phagocytes during respiratory burst
contribute to the elimination of pathogens. For example,
recent experiments demonstrated that ROS inhibit
human cytomegalovirus (HCMV) infection [65].
Platelet phagocyte function
Accumulating evidence suggests that, during direct
interaction of viral pathogens with human platelets,
there is a phagocytosis of viral pathogens by platelets
and so enables their transport for a prolonged time.
During viral infections there will be expression of
P-selectin and PS, which increases platelet-leukocyte in-
teractions and promoting phagocytosis of platelets and
viruses by macrophages [23, 43].
HIV is best example to show phagocytosis activity of
platelets and conducted research showing that, in plate-
lets incubated with HIV; HIV antigen was found in
engulfing vacuoles and the open canalicular system
(OCS) and also Immunogold labelling for the viral core
protein p24 confirmed the presence of HIV within plate-
lets, which is also true in vivo [66].
Another finding also support phagocytosis role of
platelets and platelet suspension incubated with influ-
enza virus were observed by electron microscope, and
finding shows that platelets found with virus containing
vacuoles, which suggesting that the platelets had rapidly
phagocytosed the viruses. Phagocytosis of influenza virus
by platelets may play an important role in the occur-
rence of thrombocytopenia during influenza infection
and may also a mechanism of virus clearance during in-
fection [67]. Similar finding is observed in the role of
platelets in the clearance of respiratory syncytial virus
(RSV) by internalizing viral particles and by enhancing
type I IFN production from peripheral blood mono-
nuclear cells [68].
Platelets interaction with other immune cells
In addition of direct interaction with pathogens and se-
cretion of antimicrobial agents, platelets also interact
with other immune cells. After activation platelets se-
crete a number of chemokines attracting neutrophils as
well as cytokines CD40L and IL-1β which inflame
endothelial cells. Inflamed endothelial cells express an
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array of adhesion molecules, such as ICAM-1, VCAM-
1, P and E-selectin, promoting neutrophils recruitment
[52]. P-Selectin interacts with P -selectin glycoprotein
ligand-1 (PSGL-1) and expressed on the surface of
leukocytes. This interaction cause, leukocyte mediated
immune responses during viral infections by phagocyt-
osis and enhanced reactive oxygen production of
neutrophils [69].
Interaction of CD40L on T cells with CD40 on B cells
is of paramount importance for the development and
function of the humoral immune system. Recent report
also indicates that platelets express CD40L when they
are activated and interact with CD40 of leukocytes and
increases reactive oxygen species (ROS) production by
neutrophils which enhance their capacity to phagocytose
pathogens [17, 52].
Human cytomegalovirus (HCMV) bind to platelet re-
ceptor, TLR 2, that are found on platelet which causes
activation and degranulation of HCMV-activated platelet
and cause platelets binding to and activate neutrophils
results in neutrophils mediated immune response [17].
Also in patients infected with dengue virus, there is dir-
ect interaction between platelets and antigen which
activate platelets. These activated platelets bind with
monocytes and help to enhance immune response for
pathogen [70].
Platelets have antigen presenting role [17]. Demon-
strated evidences shows that, platelets express T cell
costimulatory molecules; process and present antigen in
MHC class I, and directly activate naive T cells in a
platelet MHC class I-dependent manner. Platelets
present pathogen derived antigen to promote T cell re-
sponses in vivo; which proofs the novel antigen presen-
tation role of platelets [71]. In a murine model of
lymphocytic choriomeningitis virus (LCMV) infection,
platelets prevented lethal hemorrhagic anemia by pro-
moting cytotoxic T lymphocyte (CTL) dependent clear-
ance of the virus [72].
Conclusion
Beyond their primary role in hemostasis, platelets also
play a main role in defending viral pathogens. Much
more experimental studies give evidence for the anti-
viral role of platelet and clearly show the binding cap-
acity of platelets with different viral pathogens with
their receptors. Platelets activated and initiate their
antimicrobial host defense by sensing the presence of
pathogens or inflammation through immune receptors
such as immunoglobulin or complement receptors and
TLRs. After activation platelets secrete a number of
chemokines that attract other immune cells which is
contribute for the clearance of viruses. Platelet has dir-
ect antimicrobial functions that are mediated by secre-
tion of antimicrobial molecules including platelet
microbicidal peptides and kinocidins. This antimicro-
bial peptides releases during platelets activation and kill
viral pathogens. The other antiviral role of platelets is
killing of viruses by phagocytosis. It is widely accepted
that the ROS produced by phagocytes during respira-
tory burst contribute to the elimination of pathogens.
Platelets also produce ROS upon activation which in-
hibit viruses.
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